Regeneron Pharmaceuticals (NASDAQ: REGN), a biotechnology company, has signed a research collaboration and option licencing agreement with United States-based Vyriad, it was reported yesterday.
The contract has been signed to discover and develop new oncolytic virus-based treatments for treating various forms of cancer.
The companies will also sign a five year research contract to use Regeneron's VelociSuite technologies to design and test Vesicular Stomatitis Virus-based oncolytic virus treatments. The firms will commence a phase two clinical study in 2020 to evaluate Regeneron's PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with Vyriad's oncolytic virus Voyager-V1 in multiple types of cancer. Under the terms of the deal, Vyriad will secure an upfront payment, while Regeneron will make an equity investment in the company.
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Phrontline Biopharma doses first patient in TJ101 Phase 1 clinical trial
Gene Solutions' mitochondrial therapy platform targeting neurological diseases secures patent
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Avidity Biosciences prices upsized common stock public offering
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Endo to share PFI and PFA data at American Orthopaedic Foot & Ankle Society Annual Meeting